EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual‐Method Analysis Using Propensity Score Matching and Multivariable Regression

Tirofiban zur Vorbeugung einer frühen neurologischen Verschlechterung beim akuten ischämischen Schlaganfall innerhalb von 48 Stunden nach Symptombeginn: Evidenz aus einer Dual-Methoden-Analyse mit Propensity-Score-Matching und multivariabler Regression

Qianru Wen iD, Ying Zhao iD, Yongbing Deng, Shaobin Guan, Siqi Zhang, Jieming Zhou, Pengtao Zhu, Xuejiao Fan, Junjie Li, Yang Chen, Guoqing Cai, Yihong Huang und 2 weitere

CNS Neuroscience & Therapeutics · 2025-12 · 31 (12)

DOI: 10.1002/cns.70718 ↗

Auf einen Blick

Bei AIS ohne LVO war i.v. Tirofiban innerhalb von 48 Stunden mit weniger END verbunden als orale Plättchenhemmung. Auch frühe und spätere neurologische Verbesserungen traten häufiger auf.

Fragestellung

Senkt i.v. Tirofiban bei AIS ohne LVO innerhalb von 48 Stunden nach Symptombeginn das Risiko einer frühen neurologischen Verschlechterung?

Methode

Multizentrische prospektive Studie mit multivariabler Regression und Propensity-Score-Matching; Einschluss innerhalb von 48 h nach Beginn, NIHSS 4–15.

Ergebnisse

371 Patient:innen: 198 mit Tirofiban, 173 mit oraler Plättchenhemmung. END: 9,6 % vs. 18,0 % (p = 0,038) bzw. 10,6 % vs. 19,7 % (p = 0,031). Keine symptomatische intrakranielle Blutung in beiden Gruppen.

Schlussfolgerung der Autor:innen

Bei AIS ohne LVO reduzierte frühes i.v. Tirofiban innerhalb von 48 Stunden das Risiko für END und förderte die neurologische Besserung ohne erhöhtes Blutungsrisiko.

Kernaussagen

  • END seltener unter Tirofiban als unter oraler Plättchenhemmung
  • Keine symptomatische intrakranielle Blutung in beiden Gruppen
  • Besonderer Nutzen in der BAD-Subgruppe

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 28.12.2025. Verfasst von Qianru Wen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Sixth Affiliated Hospital of Jinan University, Dongguan, China. Hauptthemen laut MEDLINE: Tirofiban, Ischemic Stroke, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dongguan Science and Technology Bureau, Medical Joint Fund of Jinan University, Science and Technology Projects in Guangzhou.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies have indicated the potential benefits of tirofiban in preventing early neurological deterioration (END) in acute ischemic stroke (AIS) within 24 h of symptom onset. However, its efficacy and safety over a broader time window require further evaluation.

Methods

This multicenter study analyzed prospective data from AIS patients without large vessel occlusion (LVO), enrolled within 48 h of onset and with baseline NIHSS scores of 4–15. Participants received either intravenous tirofiban or oral antiplatelet therapy. The primary efficacy endpoint was the occurrence of END (increase in NIHSS score ≥ 2 points within 7 days). The primary safety endpoint was intracranial hemorrhage within 90 days. The study employed a combined analysis method of multivariable regression and propensity score matching (PSM).

Results

Among 371 enrolled patients (198 in the tirofiban group, 173 in the oral antiplatelet group), compared with the oral antiplatelet group, the incidence of END in the tirofiban group was significantly lower, as indicated by multivariate regression analysis (9.6% vs. 18.0%, p = 0.038) and PSM (10.6% vs. 19.7%, p = 0.031). Both statistical methods indicated that intravenous tirofiban can significantly facilitate early neurological improvement in patients at 7 and 14 days ( p < 0.05) and enhance the probability of a mRS score of 0–2 at 90 days ( p < 0.05). Subgroup analysis indicated particular benefit for patients with branch atheromatous disease (BAD) ( p = 0.041). No symptomatic intracranial hemorrhage occurred in either group.

Conclusion

For AIS patients without LVO, early intravenous tirofiban within 48 h of onset effectively reduced the risk of END and promoted early or long‐term neurological improvement without increasing bleeding risk, suggesting a potential therapeutic benefit in an extended time window, especially for the BAD subtype. Trail Registration Chinese Clinical Trial Registry ( chictr.org.cn ): ChiCTR2200061110.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirofibanIschemic StrokePlatelet Aggregation InhibitorsHumansMaleFemaleAgedMiddle AgedPropensity ScoreProspective StudiesAged, 80 and overTime FactorsMultivariate AnalysisTreatment Outcome

Stichwörter der Autor:innen

Tirofibanacute ischemic strokeearly neurological deteriorationmultivariable regressionnon‐large vessel occlusionpropensity score matching

Substanzen

TirofibanPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
  • Dongguan Key Laboratory of Central Nervous System Injury and Repair, Dongguan, China.
  • Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Neurology, Dongguan Houjie Hospital, Dongguan, China.
  • Department of Neurology, Dongguan Dalang Hospital, Dongguan, China.

ORCID-Profile: Qianru Wen, Ying Zhao, Heng Meng

Förderung

  • Dongguan Science and Technology Bureau
  • Medical Joint Fund of Jinan University
  • Science and Technology Projects in Guangzhou
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Medical Science and Technology Research of Guangdong Province
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Wen, Q., Zhao, Y., Deng, Y., Guan, S., Zhang, S., Zhou, J., Zhu, P., Fan, X., Li, J., Chen, Y., Cai, G., Huang, Y., Zheng, S., & Meng, H. (2025). Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual‐Method Analysis Using Propensity Score Matching and Multivariable Regression. CNS Neuroscience & Therapeutics, 31(12). https://doi.org/10.1002/cns.70718

Vancouver

Wen Q, Zhao Y, Deng Y, Guan S, Zhang S, Zhou J, et al. Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual‐Method Analysis Using Propensity Score Matching and Multivariable Regression. CNS Neuroscience & Therapeutics. 2025;31(12). doi:10.1002/cns.70718

BibTeX
@article{Wen2025,
  author = {Wen, Qianru and Zhao, Ying and Deng, Yongbing and Guan, Shaobin and Zhang, Siqi and Zhou, Jieming and Zhu, Pengtao and Fan, Xuejiao and Li, Junjie and Chen, Yang and Cai, Guoqing and Huang, Yihong and Zheng, Shugong and Meng, Heng},
  title = {Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual‐Method Analysis Using Propensity Score Matching and Multivariable Regression},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  volume = {31},
  number = {12},
  doi = {10.1002/cns.70718}
}
Kostenlos starten →